A5037682627- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Attention Deficit Hyperactivity Disorder
- Cancer Immunotherapy and Biomarkers
- Management of metastatic bone disease
- Minimally Invasive Surgical Techniques
- Intraperitoneal and Appendiceal Malignancies
- Testicular diseases and treatments
- Reproductive System and Pregnancy
- Neurological disorders and treatments
- Cancer survivorship and care
- Children's Physical and Motor Development
- Maternal and fetal healthcare
- Advancements in Semiconductor Devices and Circuit Design
- Ferroptosis and cancer prognosis
- Renal cell carcinoma treatment
- Metastasis and carcinoma case studies
- Immune Cell Function and Interaction
- Lymphatic System and Diseases
University of Duisburg-Essen
2016-2025
Essen University Hospital
2016-2025
Klinik für Frauenheilkunde
2014-2024
Olgahospital
2023
Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe
2023
Hôpital Lyon Sud
2019
Centre Léon Bérard
2019
German Cancer Research Center
2014-2018
Heidelberg University
2014-2018
German Marine Research Consortium
2017
Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer a BRCA mutation. The effect of combining olaparib and bevacizumab patients regardless mutation status is unknown.
•First PARPi trial to show clinically meaningful OS benefit in HRD+ (BRCA/non-BRCA) newly diagnosed advanced ovarian cancer.•5-Year rate disease was 66% with olaparib + bevacizumab versus 48% placebo bevacizumab.•Forty-six percent of patients receiving were progression free at 5 years, 19% on alone.•No new safety signals observed, and the incidence myelodysplastic syndrome/acute myeloid leukemia remained low.•Maintenance as a standard care may enhance potential for cure this setting....
Abstract BACKGROUND Platinum resistance constitutes one of the most recognized clinical challenges for ovarian cancer. Notably, detection primary tumor-based excision repair cross-complementation group 1 (ERCC1) protein by immunohistochemistry was recently shown to be inaccurate prediction platinum resistance. On basis previous finding that circulating tumor cells (CTC) in blood cancer patients are prognostically significant, and given our hypothesis negative prognostic impact CTC may arise...
Abstract Expression of the non-classical human leukocyte antigen-G (HLA-G) promotes cancer progression in various malignancies including epithelial ovarian (EOC). As single nucleotide polymorphisms (SNPs) HLA-G 3′ untranslated region (UTR) regulate expression, we investigated 3′UTR haplotypes arranged by SNPs healthy controls (n = 75) and primary EOC patients 79) determined soluble (sHLA-G) levels. Results were related to clinical status outcome. Although haplotype frequencies similar...
// Issam Chebouti 1, 4 , Sabine Kasimir-Bauer Paul Buderath Pauline Wimberger 2, 3, Siegfried Hauch 5 Rainer Kimmig and Jan Dominik Kuhlmann 1 Department of Gynecology Obstetrics, University Hospital Essen, 45147 Germany 2 Medical Faculty Carl Gustav Carus, Technische Universität Dresden, 01307 3 National Center for Tumor Diseases (NCT), Partner Site 69120 Heidelberg, German Cancer Consortium (DKTK), Dresden Research (DKFZ), QIAGEN, 40724 Hilden, Correspondence to: Kuhlmann, email:...
Introduction: Response to platinum-based therapy is a major prognostic factor in epithelial ovarian cancer (EOC) and reliable biomarkers are urgently needed identify patients at high risk. Since ligands of the Programmed Death Receptor-1 (PD-L1 PD-L2) play crucial role within tumor microenvironment for tumorigenesis, we investigated levels sPD-L1 sPD-L2 liquid biopsies serum samples, correlated results with clinical status, presence circulating cells (CTCs) disease outcome primary EOC...
Background To evaluate a potential correlation of the maximum standard uptake value (SUVmax) and minimum apparent diffusion coefficient (ADCmin) in primary recurrent cervical cancer based on integrated PET/MRI examinations. Methods 19 consecutive patients (mean age 51.6 years; range 30–72 years) with histopathologically confirmed (n = 9) or suspected tumor recurrence 10) were prospectively enrolled for an examination. Two radiologists performed consensus reading random order, using dedicated...
We recently showed that the presence of ERCC1+CTCs is an independent predictive biomarker for platinum-resistance and poor prognosis ovarian cancer. The goal our current research was to determine how auxiliary assessment ERCC1-transcripts influences overall CTC-detection rate. extended this investigation from initially setting paired pre- post-therapeutic blood analysis in order see, whether dynamics mirror response chemotherapy.65 Paired samples (10ml) primary cancer patients at diagnosis...
The optimal application of maintenance PARP inhibitor therapy for ovarian cancer requires accessible, robust, and rapid testing homologous recombination deficiency (HRD). However, in many countries, access to HRD is problematic the failure rate high. We developed an academic test support treatment decision-making.Genomic Instability Scar (GIScar) was through targeted sequencing a 127-gene panel determine status. GIScar trained from noninterventional study with 250 prospectively collected...
Abstract Background Extracellular vesicle (EV)-associated microRNAs (miRNAs) have been suggested as promising biomarkers for blood-based cancer diagnosis. However, one of the major limitations use EVs with diagnostic purpose is lack standardized EV-profiling techniques. In this regard, objective our study was to design an integrated next-generation sequencing (NGS)-based workflow analyzing signature EV-associated miRNA in plasma platinum-resistant ovarian patients. Methods For EV-extraction,...
Anatomical and functional aspects of the lymphatic drainage uterine corpus in endometrial cancer are demonstrated. Main pathway runs along upper pelvic from artery first line to medial external iliac nodes, followed by lateral common node basin. The second important ovarian vessels directly paraaortic nodes. Pathways may visualized best injection indocyanine green (ICG) into uterus. In contrast cervical injection, can only be marked corporal injection. Lymphatic works downstream (peripheral...
<title>Abstract</title> The prevalence of obesity has risen significantly, affecting over 19% the German population. Obesity is frequently associated with endometrial cancer, presenting considerable challenges in pre-, intra- and postoperative management. Challenges intubation, patient positioning, respiratory cardiac complications as well wound dehiscence are commonly encountered this For patients uterine surgical intervention essential for staging, symptom control, potential cure....
BACKGROUND: Uterine leiomyomas occasionally manifest as giant leiomyomas, displaying exceptional sizes within the uterus and abdominal cavity. These massive growths, although rare because of increased patient awareness, can severely distort pelvic structures pose life-threatening complications by compressing adjacent organs. We report a case who presented with severe hemodynamic instability, cardiac arrest, multiorgan failure caused 54.8-kg uterine leiomyoma, representing heaviest weight...
Despite the rarity of abdominal or chest wall metastases in ovarian cancer patients, reports have described instances isolated late recurrence at surgical incision sites. We report case an 85-year-old woman who present with a massive metastatic tumor on right anterior 42 years after undergoing total hysterectomy and bilateral salpingo-oophorectomy for primary cancer. The was resected en bloc, reconstruction performed using mesh. Histology revealed low-grade serous carcinoma. This highlights...
It is unclear whether isolated tumor cells (ITCs) in sentinel lymph nodes (SLNs) adversely affect prognosis, especially low-risk endometrial cancer. In a retrospective study, we showed worse recurrence-free survival for cancer with ITCs than the node-negative group. Our aim to evaluate likelihood of disease recurrence differs between prospective cohort patients and an historical negative SLNs. We hypothesize that will have who are node-negative. This prospective, multi-center, single-arm...
Background and Objectives To evaluate feasibility of intraoperative visualization embryologically defined organ compartments their drainage by ICG in uterine cancer. Methods Total 2.5 mg have been injected into cervix or corpus cancer patients immediately prior to surgery. Green fluorescence was intermittently detected during robotically assisted laparoscopic surgery (Firefly System®, Intuitve Surgical Inc.). 36 with without macroscopically suspicious nodes were evaluated respect...
Abstract Objective Peritoneal mesometrial resection (PMMR) plus targeted compartmental lymphadenectomy (TCL) aims at removal of the locoregional cancer field in endometrial (EC). Optimal control without adjuvant radiotherapy should be achieved concomitantly sparing systematic (LNE) for most patients. However, intermediate/high-risk EC is often definitely diagnosed postoperatively simple hysterectomy specimen. Our aim was to evaluate feasibility and safety a completing PMMR + TCL patients...